

OSSEN INNOVATION CO., LTD.
518 Shangcheng Road, Floor 17
Shanghai 200120
People's Republic of China

NOTICE OF SPECIAL MEETING OF SHAREHOLDERS

OF OSSEN INNOVATION CO., LTD.
To Be Held on September 5, 2017

To the Shareholders of Ossen Innovation Co., Ltd.:

NOTICE IS HEREBY GIVEN that a special meeting of shareholders (the "special meeting") of Ossen Innovation Co., Ltd., a British Virgin Islands company ("we," "us," "our," "Ossen" or the "Company"), will be held on Tuesday, September 5, 2017, at 10:00 a.m., Eastern time, at the offices of Ellenoff Grossman & Schole LLP, 1345 Avenue of the Americas, 11th Floor, New York, New York 10105. You are cordially invited to attend the special meeting for the following purposes:

(1) The Acquisition Proposal —to approve a share exchange agreement, as amended (the "Exchange Agreement") and related transactions providing for the acquisition (the "Acquisition") by us of 100% of the outstanding capital stock of America-Asia Diabetes Research Foundation ("AADRF"), a California corporation, from the shareholders of AADRF, in exchange for 81,243,000 of our ordinary shares (the "Exchange Shares"), an aggregate of 28,095,454 of such Exchange Shares (the "Escrow Shares") to be deposited in escrow at the closing of the Acquisition as described in this proxy statement (such proposal, the "Acquisition Proposal"). AADRF indirectly owns 90.27% of the equity interests of San Meditech (Huzhou) Co., Ltd. ("San Meditech"), a China-based medical device company engaged in the research, development and marketing of glucose control products. We refer to AADRF, San Meditech and their consolidated subsidiaries hereafter collectively as "San Meditech;"

(2) The Spin-Off Proposal — to approve a share purchase agreement dated July 19, 2017 (the "Purchase Agreement"), and related transactions providing for the sale by us of our existing business and operations to Elegant Kindness Limited, an affiliate of our Chairman, Dr. Liang Tang, in exchange for the cancellation of all of Dr. Tang's ownership interests (11,850,000 ordinary shares, representing a 59.9% interest prior to the Acquisition and the Spin-Off) in the Company (the "Spin-Off"), so that our only business upon completion of the Acquisition and the Spin-Off will be that of AADRF and its subsidiaries, and we will receive no cash consideration in connection with the Spin-Off;

(3) The Charter Amendment Proposal — to approve and adopt an amendment and restatement of the Company's memorandum and articles of association, as set forth in the draft amended and restated version of our memorandum and articles of association (the "Amended Charter"), to: (i) change the Company's name from "Ossen Innovation Co., Ltd." to "San Meditech Holdings Ltd." (the "Name Change"), (ii) increase the maximum number of shares authorized to be issued by the Company from 100,000,000 to 150,000,000 shares; (iii) automatically exchange the ordinary shares held prior to the Acquisition and Spin-Off for a newly designated Class A ordinary shares, each of which will be entitled to one vote per share and (iv) designate a new series of Class B ordinary shares to be issued to certain of the Sellers, each Class B share to be entitled to ten votes per share (the "Dual Class Structure"); and

(4) The Incentive Plan Proposal— to approve the adoption of the San Meditech 2017 Equity Incentive Plan.

After careful consideration, and upon the unanimous recommendation of the special committee of the board of directors and having reviewed the fairness opinion of Highline Research Advisors, our board of directors has unanimously approved the Exchange Agreement and the Purchase Agreement and recommends that our shareholders vote FOR adoption and approval of the Acquisition, vote FOR adoption and approval of the Spin-Off, and vote FOR all other proposals presented to our shareholders in this proxy statement. When you consider the board recommendation of these proposals, you should keep in mind that certain of our directors and officers have interests in the Acquisition and the Spin-off that may conflict with your interests as a

shareholder. See the sections entitled “The Acquisition Proposal — Certain Interests of Ossen’s Directors and Officers and Others in the Acquisition” and “The Spin-Off Proposal — Certain Interests of Ossen’s Directors and Officers and Others in the Spin-Off.”

Only holders of record at the close of business in the British Virgin Islands on August 17, 2017 (the “Record Date”) are entitled to notice of the special meeting and to vote at the special meeting and any adjournments or postponements of the special meeting. A complete list of our shareholders of record entitled to vote at the special meeting will be available for ten days before the special meeting at our principal executive offices for inspection by shareholders during ordinary business hours for any purpose germane to the special meeting. Holders of the Company’s ADSs who wish to exercise their voting rights for the underlying ordinary shares must act through JPMorgan Chase Bank, N.A., the depository of the Company’s American depository receipts program (the “Depository”).

If you own American depository shares of the Company, each representing three (3) ordinary shares (“ADSs”), you cannot vote at the special meeting directly, but you may instruct the Depository (as the holder of the ordinary shares underlying the ADSs) how to vote the ordinary shares underlying your ADSs. The Depository must receive such instructions no later than 12:00 p.m. (New York City Time) on August 31, 2017 in order to vote the underlying ordinary shares at the special meeting. Alternatively, you may vote directly at the special meeting if you convert your ADSs into ordinary shares, pay the Depository’s fees required for the conversion of the ADSs, provide instructions for the registration of the corresponding ordinary shares, and certify that you have not given, and will not give, voting instructions as to the ADSs (or alternatively, you will not vote the ordinary shares) before the close of business in New York City on August 22, 2017, and become a registered holder of ordinary shares. In addition, if you hold your ADSs through a financial intermediary such as a broker, you must rely on the procedures of the financial intermediary through which you hold your ADSs if you wish to vote at the special meeting.

If you abstain from voting, fail to cast your vote in person, fail to complete and return your proxy card in accordance with the instructions set forth on the proxy card, or fail to give voting instructions to your broker, dealer, commercial bank, trust company or other nominee, your vote will have the effect of a vote against each of the Acquisition Proposal, the Spin-Off Proposal and the Incentive Plan Proposal and will have no effect on the Charter Amendment Proposal.

Each of the Acquisition Proposal and the Spin-Off Proposal is conditioned upon each other. In addition, we would not implement the Incentive Plan Proposal or the Charter Amendment Proposal in the event that the Acquisition Proposal and the Spin-Off Proposal were not approved.

Your attention is directed to the proxy statement accompanying this notice (including the annexes thereto) for a more complete description of the proposed Acquisition, the Spin-Off, and related transactions and each of our proposals. We encourage you to read the proxy statement carefully. If you have any questions or need assistance voting your ordinary shares or ADSs, please call Johnson Zhou, Vice President, at +86 (21) 6888-8886.

By Order of the Board of Directors,

August 1, 2017

Sincerely,

/s/ Wei Hua

Wei Hua

Chief Executive Officer and Chief Financial Officer